Clinical Trial Update: Extension to a Randomized, Double-blind, Placebo Controlled Study of LCQ908 in Subjects With Familial Chylomicronemia Syndrome. [Phase 3]

View source ↗

Summary

Extension of a Phase 3 randomized, double-blind, placebo-controlled study of LCQ908 in familial chylomicronemia syndrome was terminated, with results posted in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Familial Chylomicronemia Syndrome

Drugs mentioned

• LCQ908

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Familial Chylomicronemia Syndrome (FCS) (HLP Type I) | Phase 3 | Status: TERMINATED | Results posted: 2016-11-15